- Investopedia•20 hours ago
Blockbuster drug Opdivo just got a positive recommendation in the EU to treat head and neck cancer.
- Business Wire•yesterday
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use has recommended the approval of Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy.
This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
BMY : Summary for Bristol-Myers Squibb Company - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||55.56 x 300|
|Ask||56.25 x 500|
|Day's Range||55.67 - 56.25|
|52 Week Range||46.01 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.09|
|Dividend & Yield||1.56 (2.80%)|
|1y Target Est||N/A|